tbuckley/cabot-search huggingface dataset:
Opioids in COPD: a cause of death or a marker of illness severity?
Authors: Nicholas T. Vozoris, Denis E. O'Donnell, Chaim M. Bell, Sudeep S. Gill, Paula A. Rochon
Journal: European Respiratory Journal (2016)

We thank J. Downar and colleagues for their interest in our study [1] and their contributions to this important clinical issue. Downar and colleagues view our findings through the lens of palliative medicine. We recognise the role of opioids for symptom relief among individuals with chronic obstructive pulmonary disease (COPD) as part of end-of-life care. We intentionally excluded individuals who were receiving palliative care from our study, acknowledging that "goals of care and indications for opioid use may differ in this context" [1]. Our goal was instead to evaluate, from a respiratory safety perspective, the use of opioid drugs among the broader older adult COPD population. Our previous work on opioids in COPD [2] suggests that musculoskeletal pain is probably the main reason for opioid drug receipt in the older adult COPD population rather than respiratory symptoms. Opioids combined with non-opioid agents, like acetaminophen or aspirin, accounted for close to 90% of opioid use among older adults with COPD [2]. These combination opioid/non-opioid agents are unlikely to be used in end-of-life care and their use more likely reflects treatment of musculoskeletal pain, which commonly occurs in COPD [3, 4]. Opioids were also less commonly used among individuals with COPD with frequent exacerbations [2] and this group is more likely to be troubled by refractory respiratory symptoms. Less common use of opioids by these individuals supports the argument that opioids are prescribed for reasons other than palliation of respiratory symptoms. New opioid drug use is associated with increased respiratory-related morbidity and mortality in nonpalliative COPD <http://ow.ly/wRfb303k4Yl>
ORAL01.02: Biopsies in Initial Diagnosis of Non–Small Cell Lung Cancer in US Community Oncology Practices: Implications for First-Line Immunotherapy
Authors: Maen Hussein, Donald A. Richards, Brian Ulrich, Beata Korytowsky, Dimple Pandya, John Cogswell, Cory Batenchuk, Virginia Burns
Journal: Journal of Thoracic Oncology (2016)
TCT-454 Does metallic stent design influence acute and longterm clinical outcome in second generation Everolimus-Eluting stents? Results of a single-center, 2-phase all-comer stent registry
Authors: Suzanne Fateh-Moghadam, Tobias Schlegel, martin Steeg, antonios Kilias, Wolfgang Bocksch
Journal: Journal of the American College of Cardiology (2016)
Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target
Authors: Marek Mraz, Clive S. Zent, Amy K Church, Nisar A Baig, Diane F. Jelinek, Xiaosheng Wu, Sarka Pospisilova, Stephen M. Ansell, Anne J. Novak, Thomas E. Witzig, Grzegorz S. Nowakowski
Journal: Blood (2010)
TCT-604 Non-invasive endothelial function assessment using digital reactive hyperemia correlates with 3D intravascular ultrasound and virtual histology derived plaque volume and plaque phenotype
Authors: Tomas Kovarnik, Stepan Jerabek, Zhi Chen, Andreas Wahle, Ling Zhang, Ales Kral, Jan Horak, Milan Sonka, Ales Linhart
Journal: Journal of the American College of Cardiology (2016)
TCT-443 First-in-Human Clinical Study with a Novel Drug-Filled Stent: 9-Month Clinical, Angiographic, IVUS, and OCT Outcomes from the RevElution Study
Authors: Stephen Worthley, Nicole Brilakis, Alexandre Abizaid, Ajay Kirtane, Daniel Simon, Stephan Windecker, Sandeep Brar, Ian Meredith, sharad v shetty, Ajay Sinhal, Alexandra Popma - Almonacid, Daniel Chamie, Akiko Maehara, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma
Authors: Simona Bassi, Simona Sammassimo, Federica Gigli, Giancarlo Pruneri, Paola Bertazzoni, Jessica Quarna, Emilia Cocorocchio, Daniele Laszlo, Mara Negri, Maria Lionetti, Anna Vanazzi, Alessandra Alietti, Alberto Agazzi, Angelo Gardellini, Giovanna Andreola, Lorenzo Preda, Rocco Pastano, Giovanni Martinelli
Journal: Blood (2010)
TCT-603 Traditional Coronary Risk Factors are Only Weakly Associated with Collagen Integrity of Caps over Lipid Cores in Selected Coronary Autopsy Specimens
Authors: Stephanie Grainger, Cherry Greiner, Jimmy Su, Matthew Saybolt, William Pickering, Robert Wilensky, Joel Raichlen, James Muller, Sean Madden
Journal: Journal of the American College of Cardiology (2016)
TCT-209 Optimal duration of dual antiplatelet therapy after left main coronary artery stenting: A retrospective multicenter AOI LMCA stenting registry
Authors: Hiromi Muranishi, Kyohei Yamaji, Yuhei Yamaji, Kenji Ando, Kazushige Kadota, Hirooki Higami, Kazuya Kawai, Takashi Tamura, Hiroki Sakamoto, Mamoru Toyofuku, Takeshi Morimoto, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2016)
Early intervention may limit severity of autism symptoms
Authors: Ingrid Torjesen
Journal: BMJ (2016)

An early intervention for autism designed to help parents communicate better with their child has been shown to have an effect on reducing the severity of autism symptoms for six years after the end of treatment, research published in the Lancet shows.1

The study was a follow-up of the Preschool Autism Communication Trial (PACT), in which 152 children aged 2-4 years with autism were randomly assigned to receive an early intervention for 12 months or treatment as usual.2 The intervention involved one to one clinic sessions in which parent-child interactions were videoed. The recording was then played back to the parents, and the therapist worked with the parents to enhance their …
TCT-168 Worse Outcomes in Women Compared to Men After Primary PCI in STEMI Are Not Explained by Left Ventricular Morphology and Cardiac Function: A Collaborative Patient-Level Pooled Analysis from 9 Randomized Trials
Authors: Bjorn Redfors, Ioanna Kosmidou, Rushad Dordi, Ulrich Schaefer, Holger Thiele, Manesh Patel, James Udelson, E. Magnus Ohman, Ingo Eitel, Christopher Granger, Akiko Maehara, Ajay Kirtane, Philippe Généreux, Paul Jenkins, Ori Ben-Yehuda, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
Consider national standards for daily dosages
Authors: C M Harris, J W Cullen, D J Roberts
Journal: BMJ (1994)

EDITOR, - Measuring drug volume by the number of items prescribed is unsatisfactory because of the variation in the amount per item that can and does occur; we were therefore pleased to see that M Maxwell and colleagues used the defined daily dosages set by a World Health Organisation working party as their units of volume.1,2 Some countries use their own dosages - convertible to those of the WHO when necessary - to reflect national habits. We investigated whether it …
Cover Image: The many faces of sarcoidosis
Authors: V. Wong, S.F. Hill, M. Kim, K. Tran, D.F. Murrell
Journal: British Journal of Dermatology (2016)

Funding sources: Australasian Blistering Diseases Foundation. Conflicts of interest: none declared. Dear Editor, An 80‐year‐old white man presented with dyspnoea associated with a 6‐month history of erythematous, mildly scaly plaques affecting the right side of his face, scalp, forearms and lower legs bilaterally. On the face and scalp, there were smooth yellowish‐red patches with prominent telangiectasias. Sarcoidosis was considered, particularly the angiolupoid variant. This variant (rare in Western countries) manifests as plaques with central hypopigmentation on the face, ears or scalp, which eventually evolve into annular lesions with telangiectasias.1,2 Lesional biopsies from the scalp and leg revealed non‐necrotizing epithelioid granulomas suspicious of sarcoidosis. Computed tomography of the chest identified bilateral pleural effusions with hilar lymphadenopathy. On commencement of prednisolone 40 mg daily, the appearance of his skin disease at all sites improved dramatically.
TCT-9 A per-vessel level systematic review of computed tomography-derived FFR (FFR-CT) diagnostic accuracy studies: Implications for clinical decision-making
Authors: Christopher Cook, Yousif Ahmad, Ricardo Petraco, Sukhjinder Nijjer, Matthew Shun-Shin, Rasha Al-Lamee, Yuetsu Kikuta, Yasutsugu Shiono, Jamil Mayet, Darrel Francis, Sayan Sen, Justin Davies
Journal: Journal of the American College of Cardiology (2016)
Palliative care training and burnout in oncology fellows
Authors: S. Schellhorn, D. S. Lessen, R. L. Levine, G. Panagopoulos, R. M. Arnold, S. D. Block, M. K. Buss
Journal: Journal of Clinical Oncology (2009)

9540 Background: Burnout among physicians is associated with fatigue, exhaustion, and depression, and can result in increased medical errors and sub-standard patient care. We sought to determine rates and predictors of burnout in oncology fellows. Methods: As part of a larger study on fellows' attitudes, education, and experiences in palliative care, we administered the 22 item Maslach Burnout Inventory (MBI) to second year U.S. oncology fellows. The 104 item instrument, modified from a survey of medical students, was revised after field testing and a pilot survey. The MBI measures three domains: emotional exhaustion (EE), depersonalization (DP), and personal accomplishment (PA); higher EE and DP scores and lower PA scores indicate burnout. Bivariate and multivariate analyses were used to find associations between burnout and fellow demographics, attitudes, and educational experiences. To accommodate for multiple testing, p&lt;0.01 was considered statistically significant. Results: The response rate was 63.2% (254 of 402 eligible fellows). Gender, race, and location of medical school (U.S. vs. other) did not differ between respondents and non-respondents. Among respondents, 28.1% reported high EE, 30.0% reported high DP, and 26.8% reported low PA. Over half reported burnout in at least one domain (32.9% in one, 16.5% in two, and 5.5% in all three domains). The following associations were found on multivariate analyses. Fellows who identified as white had higher rates of EE (p=0.0006) while EE was lower in those who: 1) rated their program's overall teaching ‘very good‘ or ‘excellent‘ (p=0.005), 2) felt prepared to address spiritual issues around end-of-life care (p=0.002), and 3) felt prepared to manage their own feelings about illness and dying (p=0.008). Fellows who identified as white (p=0.008) or reported dreading encounters with emotionally distressed family members (p=0.0002) had higher DP. The only factor associated with higher PA scores was agreement that doctors have a responsibility to help patients prepare for death (p&lt;0.0001). Conclusions: Over half of oncology fellows experience at least one domain of burnout. Higher quality teaching within their fellowship program and higher levels of self-assessed preparation to care for patients at the end of life are associated with lower levels of burnout. No significant financial relationships to disclose.
TCT-653 Histology of debris captured by a cerebral protection system during transcatheter valve-in-valve implantation
Authors: Tobias Schmidt, Michael Schlueter, Hannes Alessandrini, Ozan Akdag, Dimitry Schewel, Jury Schewel, Thomas Thielsen, Felix Kreidel, Ralf Bader, Maria Romero, Elena Ladich, Renu Virmani, Ulrich Schaefer, Karl-Heinz Kuck, Christian Frerker
Journal: Journal of the American College of Cardiology (2016)
PS01.49: Discrete and Limited Extent of N2 Nodes Associated with Better Outcome of Chemoradiotherapy: Effect of Pretreatment Pathological Diagnoses of N2
Authors: Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yoshinori Ito, Yuichiro Ohe
Journal: Journal of Thoracic Oncology (2016)
An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis
Authors: Omair Atiq, Jasmin Tiro, Adam C. Yopp, Adam Muffler, Jorge A. Marrero, Neehar D. Parikh, Caitlin Murphy, Katharine McCallister, Amit G. Singal
Journal: Hepatology (2016)

Although surveillance ultrasound and alpha fetoprotein (AFP) tests have minimal direct harm, downstream harms from follow‐up tests must be weighed against surveillance benefits when determining the value of hepatocellular carcinoma (HCC) screening programs. Our study's aims were to characterize prevalence and correlates of surveillance benefits and harms in cirrhosis patients undergoing HCC surveillance. We conducted a retrospective cohort study among patients with cirrhosis followed at a safety‐net health system between July 2010 and July 2013. We recorded surveillance‐related benefits, defined as early tumor detection and curative treatment, and surveillance‐related physical harms, defined as computed tomography or magnetic resonance imaging scans, biopsies, or other procedures performed for false‐positive or indeterminate surveillance results. Sociodemographic and clinical correlates of surveillance harms were evaluated using multivariable logistic regression. We identified 680 patients with cirrhosis, of whom 78 (11.5%) developed HCC during the 3‐year study period. Of the 48 (61.5%) HCCs identified by surveillance, 43.8% were detected by ultrasound, 31.2% by AFP, and 25.0% by both surveillance tests. Surveillance‐detected patients had a higher proportion of early HCC (70.2% vs. 40.0%; P = 0.009), with no difference in tumor stage between ultrasound‐ and AFP‐detected tumors ( P = 0.53). Surveillance‐related physical harms were observed in 187 (27.5%) patients, with a higher proportion of ultrasound‐related harm than AFP‐related harm (22.8% vs. 11.4%; P &lt; 0.001). Surveillance‐related harms were associated with elevated ALT (odds ratio [OR], 1.87; 95% confidence interval [CI], 1.26‐2.76), thrombocytopenia (OR, 2.06; 95% CI, 1.26‐3.38), and hepatology subspecialty care (OR, 1.63; 95% CI, 1.09‐2.42). Conclusion : Over one fourth of patients with cirrhosis experience physical harm for false‐positive or indeterminate surveillance tests—more often related to ultrasound than AFP. Interventions are needed to reduce surveillance‐related harm to increase the value of HCC screening programs in clinical practice. (H epatology 2017;65:1196‐1205).
The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes
Authors: Jieun Uhm, Nada Hamad, Vikas Gupta, John Kuruvilla, Hans A. Messner, Matthew Seftel, Jeffrey H. Lipton, Dennis D. Kim
Journal: Blood (2014)
TCT-451 Two-year outcomes after revascularization with a biodegradable polymer ultra-thin strut sirolimus eluting stent and a biodegradable polymer biolimus-eluting stent. From the SORT OUT VII trial
Authors: Lisette Okkels Jensen, Michael Maeng, Bent Raungaard, Knud Noerregaard Hansen, Johnny Kahlert, Svend Eggert Jensen, Hans Erik Bøtker, Henrik Hansen, Jens Flensted Lassen, Evald Christiansen
Journal: Journal of the American College of Cardiology (2016)
Molecular pathways and gene ontology categories in association with response to combination chemotherapy plus bevacizumab in inflammatory and locally advanced breast cancer
Authors: S. M. Swain, S. M. Steinberg, Z. Modrusan, V. Smith, F. de Sauvage, S. X. Yang
Journal: Journal of Clinical Oncology (2007)

509 Background: Inflammatory breast cancer (IBC) is an extremely aggressive subtype of locally advanced breast cancer (LABC) accounting for 1% to 6% of all breast cancers. The overall response rate to a combined modality therapy is 61.4%-83.5% and 15-year overall survival is 20%. Identification of Gene Ontology (GO) category or molecular pathway signature to distinguish subsets of patients with distinct clinical outcomes is imperative. Methods: 20 patients with IBC and 1 with LABC received one cycle of bevacizumab at 15mg/kg followed by six cycles of doxorubicin at 50mg/m 2 and docetaxel at 75mg/m 2 plus bevacizumab before surgery. Response to combination chemotherapy plus bevacizumab was measured with radiologic imaging modalities. Gene expression profiles from 20 tumor biopsies at baseline (1 with PD had inadequate biopsy) were measured with Agilent Whole Human Genome arrays and utilized to correlate with clinical response. Results: 14 (67%) of 21 patients (95% CI, 43%-85.4%) had a clinical partial response (PR), 5 had stable disease (SD) and 2 had progressive disease (PD). Of 103 molecular pathways, those of the stathmin and breast cancer resistance to antimicrotubule agents, and BTG family proteins and cell cycle regulation were significantly associated with response (PR versus SD+PD; P = .002 and .003). Members of the stathmin pathway are cyclin B1, cell division cycle 2, stathmin 1 (kinase interacting with leukemia-associated gene), and mitogen-activated protein kinase 13; BTG family members are retinoblastoma 1, CCR4-NOT transcription complex, subunit 7, and B-cell translocation gene 1. Sixteen of 965 GO classes were differentially expressed between patients with PR and PD plus SD (P &lt; .005). Those include GO categories of transcription factor complex (14 genes; P = .00009), extracellular matrix (69 genes; P = .0006), and protein kinase activity (90 genes; P = .002). Tumor differentiation, ER, HER2/neu, and p53 were not associated with clinical response. Conclusions: Two pathways that regulate microtubule stability and cell cycle, and 16 GO categories are significantly associated with the response to the combination chemotherapy of docetaxel-doxorubicin plus bevacizumab. No significant financial relationships to disclose.
TCT-49 Two-year clinical outcome of Everolimus-eluting bioresorbable scaffold vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction— TROFI II trial
Authors: Stephan Windecker, Taku Asano, Lorenz Raber, Salvatore Brugaletta, Manel Sabate, Yoshinobu Onuma, Patrick Serruys
Journal: Journal of the American College of Cardiology (2016)
The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis
Authors: Shelly Maman, Orit Sagi-Assif, Weirong Yuan, Ravit Ginat, Tsipi Meshel, Inna Zubrilov, Yona Keisari, Weiyue Lu, Wuyuan Lu, Isaac P. Witz
Journal: Cancer Research (2016)

Soluble pulmonary factors have been reported to be capable of inhibiting the viability of cancer cells that metastasize to the lung, but the molecular identity was obscure. Here we report the isolation and characterization of the beta subunit of hemoglobin as a lung-derived antimetastatic factor. Peptide mapping in the beta subunit of human hemoglobin (HBB) defined a short C-terminal region (termed Metox) as responsible for activity. In tissue culture, both HBB and murine HBB2 mediated growth arrest and apoptosis of lung-metastasizing neuroblastoma cells, along with a variety of other human cancer cell lines. Metox acted similarly and its administration in human tumor xenograft models limited the development of adrenal neuroblastoma tumors as well as spontaneous lung and bone marrow metastases. Expression studies in mice indicated that HBB2 is produced by alveolar epithelial and endothelial cells and is upregulated in mice bearing undetectable metastasis. Our work suggested a novel function for HBB as a theranostic molecule: an innate antimetastasis factor with potential utility as an anticancer drug and a biomarker signaling the presence of clinically undetectable metastasis. Cancer Res; 77(1); 14-26. ©2016 AACR.
Sickle Cell Disease Glomerulopathy In Five Subsaharian African Countries: Results Of The Cadre Study
Authors: Brigitte Ranque, Marie Michèle Thiam, Dapa Aly Diallo, Saliou Diop, Ibrahima Diagne, Ibrahima Sanogo, Gustave Koffi, Kouakou Boidy, Luc Sica, Guillaume Wamba, Suzanne Belinga, Pierre Louis Tharaux, Xavier Jouven
Journal: Blood (2013)
Deficiency of Rac1 and Rac2 GTPases Perturbs Erythroid Proliferation and Differentiation but Not Enucleation.
Authors: Theodosia A. Kalfa, Suvarnamala Pushkaran, Jose A. Cancelas, Michael Jansen, James F. Johnson, Kristen Hebel, David A. Williams, Yi Zheng
Journal: Blood (2006)
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).
Authors: Ilaria Iacobucci, Anna Ferrari, Alexander Kohlmann, Cristina Papayannidis, Claudia Venturi, Margherita Perricone, Maria Chiara Fontana, Paola Bresciani, Sabina Chiaretti, Mariachiara Abbenante, Stefania Paolini, Sarah Parisi, Federica Cattina, Simona Soverini, Domenico Russo, Fabrizio Pane, Robin Foà, Mario Luppi, Torsten Haferlach, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2012)
Variations in Abdominal Aortic Aneurysm Care: A Report From the International Consortium of Vascular Registries
Authors: Adam W. Beck, Art Sedrakyan, Jialin Mao, Maarit Venermo, Rumi Faizer, Sebastian Debus, Christian-Alexander Behrendt, Salvatore Scali, Martin Altreuther, Marc Schermerhorn, Barry Beiles, Zoltan Szeberin, Nikolaj Eldrup, Gudmundur Danielsson, Ian Thomson, Pius Wigger, Martin Björck, Jack L. Cronenwett, Kevin Mani
Journal: Circulation (2016)

This project by the ICVR (International Consortium of Vascular Registries), a collaboration of 11 vascular surgical quality registries, was designed to evaluate international variation in the contemporary management of abdominal aortic aneurysm (AAA) with relation to recommended treatment guidelines from the Society for Vascular Surgery and the European Society for Vascular Surgery.
TCT-609 Cardiac Erosion after the Transcatheter Closure of Atrial Septal Defect Using Amplatzer Septal Occluder: Japanese Nationwide Experience
Authors: Teiji Akagi, Satoshi Yazaki, Hideshi Tomita, Morimasa Takayama, Hidehiko Hara, JPICCVIT registry
Journal: Journal of the American College of Cardiology (2016)
Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview
Authors: Anurag K. Singh, Joseph P. McGuirk
Journal: Cancer Research (2016)

The field of hematopoietic stem cell transplant (HSCT) has made ground-breaking progress in the treatment of many malignant and nonmalignant conditions. It has also pioneered the concepts of stem cell therapy and immunotherapy as a tool against cancer. The success of transplant for hematologic malignancies derives both from the ability to treat patients with intensive chemoradiotherapy and from potent graft-versus-leukemia (GVL) effects mediated by donor immunity. Additionally, HSCT has been a curative therapy for several nonmalignant hematologic disorders through the provision of donor-derived hematopoiesis and immunity. Preclinical and clinical research in the field has contributed to an advanced understanding of histocompatibility, graft-versus-host disease (GVHD), GVL effect, and immune reconstitution after transplant. Improved donor selection, tailored conditioning regimens, and better supportive care have helped reduce transplant-related morbidity and mortality and expanded access. The development of unrelated donor registries and increased utilization of cord blood and partially matched related donor transplants have ensured a donor for essentially everyone who needs a transplant. However, significant barriers still remain in the form of disease relapse, GVHD infectious complications, and regimen-related toxicities. Recent developments in the field of cellular therapy are expected to further improve the efficacy of transplant. In this review, we discuss the current science of HSCT from a historical perspective, highlighting major discoveries. We also speculate on future directions in this field. Cancer Res; 76(22); 6445-51. ©2016 AACR.